retatrutide triple agonist obesity Eli Lilly's shows promising weight loss results in phase 3 trial Retatrutide Explained: The Triple Agonist

The mechanism involves glucose-dependent insulin secretion, meaning insulin release occurs primarily when blood glucose levels are elevated, thereby reducing the risk of hypoglycemia when used as monotherapy

Some patients also benefit from exploring alternative GLP-1 compounds

Insulin resistance increases

Wells Fargo has already flagged Hershey, Conagra and Krispy Kreme as vulnerable - concentrated in categories that are easiest to cut when appetite drops

Metformin and GLP-1 medications are frequently prescribed together for patients who have both type 2 diabetes and obesity

Gastrointestinal symptoms are among the most commonly reported side effects of retatrutide and related agents